Q1 Earnings Forecast for Amgen Issued By William Blair

Amgen Inc. (NASDAQ:AMGN) – William Blair issued their Q1 2026 earnings estimates for Amgen in a report released on Wednesday, March 5th. William Blair analyst M. Phipps anticipates that the medical research company will post earnings per share of $4.42 for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Amgen’s current full-year earnings is $20.62 per share. William Blair also issued estimates for Amgen’s Q2 2026 earnings at $5.00 EPS and Q3 2026 earnings at $5.24 EPS.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%.

A number of other research firms also recently issued reports on AMGN. Piper Sandler boosted their target price on shares of Amgen from $310.00 to $329.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. Piper Sandler Companies restated an “overweight” rating and set a $310.00 target price on shares of Amgen in a research report on Thursday, January 2nd. Leerink Partners cut their price objective on shares of Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Bank of America lifted their price objective on shares of Amgen from $275.00 to $294.00 and gave the company an “underperform” rating in a report on Wednesday. Finally, Wells Fargo & Company reaffirmed an “equal weight” rating on shares of Amgen in a report on Wednesday, February 5th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $314.95.

Amgen Trading Up 2.2 %

NASDAQ AMGN opened at $324.86 on Friday. The company has a market capitalization of $174.52 billion, a PE ratio of 43.03, a P/E/G ratio of 2.63 and a beta of 0.53. The company has a fifty day moving average of $286.14 and a 200 day moving average of $299.69. Amgen has a 1 year low of $253.30 and a 1 year high of $346.85. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95.

Hedge Funds Weigh In On Amgen

Several institutional investors and hedge funds have recently bought and sold shares of the company. Alpha Wealth Funds LLC acquired a new position in Amgen in the 4th quarter valued at about $522,000. Copia Wealth Management acquired a new position in Amgen in the 4th quarter valued at about $45,000. IronOak Wealth LLC. acquired a new position in Amgen in the 4th quarter valued at about $313,000. Wood Tarver Financial Group LLC acquired a new position in Amgen in the 4th quarter valued at about $111,000. Finally, Kilter Group LLC acquired a new position in Amgen in the 4th quarter valued at about $334,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 1,589 shares of the company’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the sale, the senior vice president now owns 7,210 shares of the company’s stock, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jonathan P. Graham sold 25,045 shares of the company’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the sale, the executive vice president now directly owns 28,987 shares of the company’s stock, valued at approximately $8,496,669.44. This represents a 46.35 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 69,341 shares of company stock valued at $20,644,335. Corporate insiders own 0.69% of the company’s stock.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be paid a dividend of $2.38 per share. The ex-dividend date is Friday, May 16th. This represents a $9.52 annualized dividend and a yield of 2.93%. Amgen’s dividend payout ratio is presently 126.09%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.